Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)
Phase of Trial: Phase II/III
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Pegargiminase (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Therapeutic Use
- Acronyms ATOMIC
- Sponsors Polaris Pharmaceuticals
- 21 Feb 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 21 Feb 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Aug 2018.
- 06 Jun 2017 Trial design of the study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.